Rosetta Genomics and Halozyme Therapeutics: Wait for Better News

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Rosetta Genomics and Halozyme Therapeutics both posted losses in Thursday’s trading session, on events that were outside of their control. Rosetta saw its earnings results post another loss while finding additional outside sources of revenues, while Halozyme had an unexpected pause brought to their FDA clinical trial expectations.

RDI Initiates
Coverage:

Rosetta Genomics Ltd. https://ub.rdinvesting.com/news/?ticker=ROSG

Halozyme
Therapeutics, Inc. https://ub.rdinvesting.com/news/?ticker=HALO

Rosetta Genomics fell 16.72% to close at $2.79 on Thursday. The stock traded between $3.35 and $2.79 on a volume of 217,823 shares traded. The company focuses on genomic diagnostics designed to improve treatment decisions through making timely and accurate diagnostic information available to physicians. The company’s main product is the RosettaGX Reveal, a unique microRNA classifier for diagnosis of cancer in indeterminate thyroid nodules.

In financial news, the company made available its 4th quarter financial results. It had raised $4.6 million through one prominent institutional healthcare investor. Rosetta has posted a 4th quarter GAAP loss of $4.8 million or $2.73 a share as compared to $6.7 million or $4.39 a share for the 4th quarter of 2015. The company has also improved its operating losses from $5.1 million in Q4 2015 to $4.3 million in Q4 2016 while reducing R&D expenses by nearly $200,000 compared to the same reporting period a year ago.

RosettaGX Reveal remains the company’s future revenue source as the company expects revenues of $4 million to $5 million from RosettaGX Reveal in fiscal year 2017. The Journal of Clinical Pathology, a peer-reviewed journal, published a favorable clinical validation of RosettaGX Reveal. The product was also a cover feature on another peer reviewed journal, Cancer Cytopathology.

Access RDI’s Rosetta Genomics Research Report at: https://ub.rdinvesting.com/news/?ticker=ROSG

Halozyme Therapeutics dropped 8.82% to close at $13.03 on Thursday. The stock traded between $13.29 and $12.44 on a volume of 5.94 million shares traded. In its latest update on March 29th, Halozyme management has expressed hope that the company would be able to have its PEGPH20 plus modified FOLFIRINOX chemotherapy treatment evaluated soon, as they were informed by SWOG, an independent network of researchers that all entries to the Phase I/II studies have been temporarily closed.

On Wednesday, March 29th, the Oncologic Drug Advisory Committee of the FDA voted 11 – 0 that the benefit/risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favorable for patients. The drug is co-formulated with Halozyme’s recombinant human hyaluronidase and was approved for use in Europe in 2014. Currently it is marketed as a subcutaneous formula of rituximab.

Access RDI’s Halozyme Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=HALO

Our Actionable Research on Rosetta Genomics Ltd. (NASDAQ: ROSG) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458647